Nyrada Inc.

NYR

Nyrada, Inc. operates as a pre-clinical stage, drug development company. The company is headquartered in Gordon, New South Wales. The company went IPO on 2020-01-16. The Company’s two lead programs are focused on cholesterol-lowering and brain injury. These programs are developing an oral, small molecule cholesterol-lowering drug, and a drug to reduce secondary brain damage following a stroke or traumatic brain injury (TBI). Its Cholesterol-Lowering Program is an oral PCSK9 inhibitor for the treatment of high blood LDL-cholesterol levels in patients poorly responsive to or unable to take statin drugs. Its Brain Injury Program is developing a drug to block secondary brain damage that occurs following a stroke or TBI, such as severe head trauma from contact sports, a fall, or a motor vehicle accident. The Brain Injury Program is a neuroprotectant drug to reduce the impact of long-term disability in patients who suffer a traumatic brain injury or ischemic stroke. The company is also developing new therapies.

New Zealand King Salmon Investments Limited

NZK

New Zealand King Salmon Investments Ltd. is a holding company, which engages in the farming, processing and sale of salmon products. The company is headquartered in Nelson, Nelson. The company went IPO on 2016-10-19. The firm produces and markets a diverse range of king salmon products, including fresh whole salmon, fillet, raw portions, cold smocked, wood roasted, ready to cook portion with sauce sachet, salmon and potato cakes, caviar, oil, kibble, and pet treats. The Company’s brands include Ora King, Regal Marlborough King Salmon, Southern Ocean and Omega Plus The Salmon Superfood. Ora King has a vibrant flesh color and high fat content. Regal Marlborough King salmon provides a variety of fresh salmon cuts, as well as convenient ready to cook options. Southern Ocean offers a range of packed smoked salmon products. The Company’s subsidiaries include The New Zealand King Salmon Co Limited, New Zealand King Salmon Exports Limited, The New Zealand King Salmon Pty Limited and New Zealand King Salmon.

Next Science Limited

NXS

Next Science Ltd. engages in the research, development, and distribution of technologies with bacterial issue application. The company is headquartered in Chatswood, New South Wales. The company went IPO on 2019-04-18. The firm's principal activities include development and commercialization of XBIO technology. The XBIO technology is a non-toxic technology used in solving the problems of bacterial biofilms-based infections in human health. Its XBIO technology is a non-toxic technology with efficacy in eradicating both biofilm based and free-floating bacteria. The Company’s products include XPERIENCE, Blast X, SurgX and Bactisure. The XPERIENCE product is an antimicrobial solution used to prevent surgical site infections by rinsing away debris and microorganisms. SurgX Sterile Antimicrobial Gel is used to reduce surgical site and post-surgical infections by destroying planktonic and biofilm-based bacteria within the gel with sustained effectiveness for up to five days. The Blast X is an antimicrobial wound gel.

Nextdc Limited

NXT

NextDC Ltd. engages in the operation and development of smart, secure and scalable datacenters. The company is headquartered in Brisbane, Queensland. The company went IPO on 2010-12-13. The firm is engaged in the development and operation of independent data centers in Australia. The company enables businesses through customer-focused data center operations and network solutions. The firm is an independent data center operator with a nationwide network of Tier III and Tier IV facilities in the Australian market. The company provides colocation services to local and international organizations. The company is focused on sustainability and renewable energy and delivers its customers solutions and NABERS 5-star certification. Its partner ecosystem comprises a specialized ICT community of less than 750 clouds, networks and information technology (IT) service providers. The power of its network-rich ecosystem enables its customers to source and connect with cloud platforms, service providers, and vendors to build integrated hybrid cloud deployments and scale their IT infrastructure and services.